Levee Medical Pockets $10M in Series B for Urologic Scaffold

Levee Medical, a company aiming to improve outcomes for prostate cancer surgery patients, has closed a $10 million Series B financing round.

The company said the proceeds will boost the development of its Voro urologic scaffold, an absorbable device to reduce post-prostatectomy urinary incontinence. The funds will also support ongoing clinical studies, which include an upcoming U.S. pivotal trial and current ARID studies.

“There is substantial interest in our efforts to help men get drier sooner after surgery,” said Adam Irving, CEO of Levee Medical. “We are deeply grateful for the incredible support we’ve received in bringing transformative solutions to patients and providers.”

The Voro scaffold is placed during the prostatectomy to manage the bladder neck’s geometry and maintain urethral length, both of which are critical to prevent post-op incontinence. The device seeks to reduce the incidence of stress urinary incontinence and become a solution for patients undergoing radical prostatectomy.

The company also revealed milestones in its ARID study, which has enrolled 28 patients. The feasibility study is assessing Voro’s safety and efficacy in reducing post-surgical stress urinary incontinence.

“Our experience with the Voro Urologic Scaffold has been extremely encouraging,” said Dr. Gustavo Espino, PI of the ARID study at Hospital Nacional in Panama City. “The device had an outstanding safety profile and patients have noted early improvements in continence, which translates to a considerably better quality of life post-surgery.”